A Pilot Study of Fecal Serine-Protease Activity: A Pathophysiologic Factor in Diarrhea-Predominant Irritable Bowel Syndrome

Clinical Gastroenterology and Hepatology

Volumn 5, Issue 5, 2007, Pages 550-555

  Róka, Richárd ^a   Rosztóczy, András ^b   Leveque, Mathilde ^a   Izbéki, Ferenc ^b   Nagy, Ferenc ^b   Molnár, Tamás ^b   Lonovics, János ^b   Garcia Villar, Rafael ^a   Fioramonti, Jean ^a   Wittmann, Tibor ^b   Bueno, Lionel ^a  

^a CEMAGREF   (France)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CASEIN; PANCREATIC ELASTASE; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SERINE PROTEINASE; TRYPTASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONSTIPATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DEFECATION; DIARRHEA; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES ANALYSIS; FEMALE; HUMAN; INTESTINAL DYSMOTILITY; IRRITABLE COLON; MALE; PATHOPHYSIOLOGY; PHOTOMETRY; PILOT STUDY; PROTEIN DEGRADATION; ULCERATIVE COLITIS;

ADULT; AGED; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; DIARRHEA; FECES; FEMALE; HUMANS; INTESTINAL MUCOSA; MALE; MIDDLE AGED; PILOT PROJECTS; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; SERINE ENDOPEPTIDASES;

EID: 34247539019     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2006.12.004     Document Type: Article

References (34)

1. Corazziari E. Definition and epidemiology of functional gastrointestinal disorders. Best Pract Res Clin Gastroenterol 18 (2004) 613-631
2. Drossmann D.A., Whitehead W.E., and Camillieri M. Irritable bowel syndrome: technical review for practice guideline development. Gastroenterology 112 (1997) 2120-2137
3. Talley N.J., and Spiller R. Irritable bowel syndrome: a little understood organic bowel disease?. Lancet 360 (2002) 555-564
4. Nystedt S., Lanson A.K., Aberg H., et al. The mouse proteinase-activated receptor-2 cDNA and gene. Molecular cloning and functional expression. J Biol Chem 270 (1995) 5950-5955
5. Coelho A.M., Vergnolle N., Guiard B., et al. Proteinases and proteinase-activated receptor 2: a possible role to promote visceral hyperalgesia in rats. Gastroenterology 122 (2002) 1035-1047
6. Kawao N., Ikeda H., Kitano T., et al. Modulation of capsaicin-evoked visceral pain and referred hyperalgesia by protease-activated receptors 1 and 2. J Pharmacol Sci 94 (2004) 277-285
7. Reed D.E., Barajas-Lopez C., Cottrell G., et al. Mast cell tryptase and proteinase-activated receptor 2 induce hyperexcitability of guinea-pig submucosal neurons. J Physiol 547 (2003) 531-542
8. Cenac N., Chin A.C., Garcia-Villar R., et al. PAR2 activation alters colonic paracellular permeability in mice via IFN-γ dependent and -independent pathways. J Physiol 558 (2004) 913-925
9. Ait-Belgnaoui A., Bradesi S., Fioramonti J., et al. Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: role of myosin light chain kinase. Pain 113 (2005) 141-147
10. Cenac N., Coelho A.M., N'guyen C., et al. Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol 161 (2002) 1903-1915
11. Bohm S.K., Kong W., Bromme D., et al. Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. Biochem J 314 (1996) 1009-1016
12. Vergnolle N. Modulation of visceral pain and inflammation by protease-activated receptors. Br J Pharmacol 141 (2004) 1264-1274
13. Vergnolle N., Shhaffer E., and Andrews C. Role for proteases and protease-activated receptor-2 in hyperalagaesia induced by supernatants of IBS patients biopsies. Neurogastroenterol Motil 16 (2004) 848A
14. Spiller R.C., Jenkins D., Thornley J.P., et al. Increased rectal mucosal endocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 47 (2000) 804-811
15. Marshall J.K., Thabane M., Garg A.X., et al. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther 20 (2004) 1317-1322
16. Dunlop S.P., Hebden J., Perkins A., et al. Abnormal intestinal permeability in subtypes of diarrhoea predominant IBS. Neurogastroenterol Motil 14 (2002) 586p
17. Isgar B., Herman M., Kaye M.D., et al. Symptoms of irritable bowel syndrome in ulcerative colitis in remission. Gut 24 (1983) 190-192
18. Gwee K.A., Graham J.C., McKendrick M.W., et al. Psychometris scores and persistence of irritable bowel after infectious diarrhoea. Lancet 347 (1996) 150-153
19. Neal K.R., Hebden J., and Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of irritable bowel syndrome: postal survey of patients. BMJ 314 (1997) 779-782
20. Dunlop S.P., Jenkins D., Nela K.R., et al. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 125 (2003) 1651-1659
21. Chadwick V.S., Chen W., Shu D., et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 122 (2002) 1778-1783
22. Dong W.Z., Zou D.W., Li Z.S., et al. Study of visceral hypersensitivity in irritable bowel syndrome. Chin J Dig Dis 5 (2004) 103-109
23. Barbara G., Stanghellini V., De Giorgio R., et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126 (2004) 693-702
24. Bustos D., Negri G., De Paula J.A., et al. Colonic proteinases: increased activity in patients with ulcerative colitis. Medicina (B Aires) 58 (1998) 262-264
25. Bohe M. Pancreatic and granulocytic endoproteases in faecal extracts from patients with active ulcerative colitis. Scand J Gastroenterol 22 (1987) 59-64
26. Kim J.A., Choi S.C., Yun K.J., et al. Expression of protease-activated receptor-2 in ulcerative colitis. Inflamm Bowel Dis 9 (2003) 224-229
27. Macfarlane G.T., Allison C., Gibson S.A., et al. Contribution of the microflora to proteolysis in the human large intestine. J Appl Bacteriol 64 (1988) 37-46
28. Ruseler-van Embden J.G.H., van Lieshout L.M.C., Smits S.A., et al. Potato tuber proteins efficiently inhibit human faecal proteolytic activity: implication for treatment of peri-anal dermatitis. Eur J Clin Invest 34 (2004) 303-311
29. Balsari A., Ceccarelli A., Dubini F., et al. The fecal microbial population in the irritable bowel syndrome. Microbiologica 5 (1982) 185-194
30. Swidsinski A., Khilkin M., and Orthner M. Alteration of bacterial concentration in colonic biopsies from patients with irritable bowel syndrome (IBS). Gastroenterology 116 (1999) A1
31. Si-Tahar M., Merlin D., Sitaraman S., et al. Constitutive and regulated secretion of secretory leukocyte proteinase inhibitor by human intestinal epithelial cells. Gastroenterology 118 (2000) 1061-1071
32. Nystrom M., Westin U.P., Linder C., et al. Secretory leukocyte protease inhibitor in punch biopsies from human colonic mucosa. Mediators Inflamm 10 (2001) 269-272
33. Kono K., Takahashi A., Sugai H., et al. Oral trypsin inhibitor can improve reflux esophagitis after distal gastrectomy concomitant with decreased trypsin activity. Am J Surg 190 (2005) 412-417
34. Senda S., Fujiyama Y., Bamba T., et al. Treatment of ulcerative colitis with camostat mesilate, a serine protease inhibitor. Intern Med 32 (1993) 350-354